10th Mediterranean Congress of Chemotherapy, Antalya, Turkey, 20 - 25 October 1996, pp.489-492
Sixty metastatic and recurrent breast cancer patients who had been given CMF therapy previously and had applied to the Ongology Departments of Cukurova and Ege University Medical Schools between March 1992-94, have been randomized into 2 groups for the chemotherapy program. The 30 patients in the 1(st) group were given Etoposide: 200mgxdayx5 orally every 3 weeks. in the 2(nd) group Fluorouracil:500 mgxm(2) ,Doxorubicin:50mg/m(2), Cyclophosphamide:500mg/m(2) were administered intravenously every 3 weeks. The response rates were 22/30 in the 1(st) group and 18/30 in the 2(nd) group. The duration of responses were 11 months (8-21) in the 1(st) and 9 months (4-18) in the 2(nd) group. Severe myelotoxicity was observed in 2 of the patients in the 1(st) group and in 5 of the patients in the 2(nd) group.